The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs

Gastroenterology

Volumn 134, Issue 4, 2008, Pages

  Targownik, Laura E ^a,b   Metge, Colleen J ^a,b   Leung, Stella ^a,b   Chateau, Daniel G ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; PEPTIC ULCER; PRIORITY JOURNAL; RISK REDUCTION;

EID: 41349090797     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.01.010     Document Type: Article

References (43)

1. Kasman N., and Badley E. Chapter 5: Arthritis-related prescription medications (2006), Public Health Agency of Canada, Ottawa, Ontario, Canada Volume 2007
2. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 112 (1997) 683-689
3. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
4. Langman M.J., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 1075-1078
5. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
6. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114 (1991) 257-263
7. Targownik L.E., and Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin Gastroenterol Hepatol 4 (2006) 1459-1466
8. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
9. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
10. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
11. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
12. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
13. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
14. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
15. Bocanegra T.S., Weaver A.L., Tindall E.A., et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol 25 (1998) 1602-1611
16. Agrawal N.M., Campbell D.R., Safdi M.A., et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 160 (2000) 1455-1461
17. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
18. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
19. Roos N.P. Establishing a population data-based policy unit. Med Care 37 (1999) JS15-JS26
20. Roos N.P., and Shapiro E. Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37 (1999) JS10-JS14
21. Robinson J.R., Young T.K., Roos L.L., et al. Estimating the burden of disease. Comparing administrative data and self-reports. Med Care 35 (1997) 932-947
22. Huzel L., Roos L.L., Anthonisen N.R., et al. Diagnosing asthma: the fit between survey and administrative database. Can Respir J 9 (2002) 407-412
23. Metge C., Black C., Peterson S., et al. The population's use of pharmaceuticals. Med Care 37 (1999) JS42-JS59
24. Metge C.J., Blanchard J.F., Peterson S., et al. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 96 (2001) 3348-3355
25. Targownik L.E., Metge C., Roos L., et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 102 (2007) 942-950
26. Cooper G.S., Chak A., Lloyd L.E., et al. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointest Endosc 51 (2000) 423-426
27. Raiford D.S., Perez Gutthann S., and Garcia Rodriguez L.A. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 7 (1996) 101-104
28. Rahme E., Bardou M., Dasgupta K., et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46 (2007) 265-272
29. Starfield B., Weiner J., Mumford L., et al. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 26 (1991) 53-74
30. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
31. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
32. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
33. Ray W.A., Chung C.P., Stein C.M., et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 133 (2007) 790-798
34. Wilcox C.M., Allison J., Benzuly K., et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 4 (2006) 1082-1089
35. Tannenbaum H., Bombardier C., Davis P., et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 33 (2006) 140-157
36. Raskin J.B., White R.H., Jaszewski R., et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 91 (1996) 223-227
37. Agrawal N.M., Caldwell J., Kivitz A.J., et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 21 (1999) 659-674
38. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 167 (2007) 950-955
39. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004) 1955-1960
40. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 (2005) 2989-2995
41. Dial S., Delaney J.A., Schneider V., et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175 (2006) 745-748
42. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 (2006) 2947-2953
43. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626